CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease

Mohamad Mohty

DOI: https://doi.org/10.1056/nejme2407369

IF: 158.5

2024-09-20

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 11, Page 1055-1059, September 19, 2024.

medicine, general & internal

What problem does this paper attempt to address?

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Shan He,Qi Cao,Yuhua Qiu,Jianqing Mi,Jingwu Z Zhang,Min Jin,Hailiang Ge,Stephen G Emerson,Yi Zhang,Yanyun Zhang

DOI: https://doi.org/10.4049/jimmunol.181.11.7581

2009-01-01

Abstract:Chemokines and chemokine receptors play critical roles in directing the migration of alloreactive donor T cells into graft-vs-host disease (GVHD) target organs. However, blockade of GVHD by antagonist Ab against chemokine receptors remains an elusive goal. Using a mouse model of human GVHD, we demonstrate that in vivo administration of anti-CXCR3 Ab for 21 days (long-term), but not for 7 days (short-term), inhibits alloreactive CD8(+) T cell-mediated GVHD. During a graft-vs-host reaction, infused donor CD8(+)T cells generate two subsets of potent inducers of GVHD: CXCR3(+)CD8(+) and CXCR3(-)CD8(+) T cells. Compared with CXCR(3+)CD8(+) T cells, CXCR3(-)CD8(+) T cells produce less granzyme B, Fas ligand, IFN-gamma, and TNF-alpha. Interestingly, stimulation with either dendritic cells or IL-2 induces a dynamic conversion between CXCR3(+)CD8(+) and CXCR3(-)CD8(+) T cells. Short-term anti-CXCR3 Ab treatment inhibits only CXCR3(+)CD8(+) T cell-mediated GVHD, but not the disease induced by CXCR3(-)CD8(+) T cells. Prolonged in vivo administration of anti-CXCR3 Ab significantly reduces the infiltration of alloreactive CD8+ T cells into GVHD target organs and inhibits GVHD mediated by either CXCR3(+)CD8(+) or CXCR3(-)CD8(+) T cells. Thus, we have established a novel and effective approach with the potential to give rise to new clinical methods for preventing and treating GVHD after allogeneic hematopoietic stem cell transplantation. The Journal of Immunology, 2008, 181: 7581-7592.
Targeting CSF1R in Chronic GVHD — Lessons in Translation

Stefanie Sarantopoulos

DOI: https://doi.org/10.1056/nejme2407731

IF: 158.5

2024-09-20

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 11, Page 1053-1055, September 19, 2024.

medicine, general & internal
CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice

Rachael C Adams,Dylan Carter-Cusack,Genesis T Llanes,Christopher R Hunter,Janaki Manoja Vinnakota,Marc J Ruitenberg,Jana Vukovic,Patrick Bertolino,Kirat K Chand,Julie A Wixey,Samuel P Nayler,Geoffrey R Hill,Scott N Furlan,Robert Zeiser,Kelli P A MacDonald

DOI: https://doi.org/10.1182/blood.2023022040

IF: 20.3

2024-03-07

Blood

Abstract:Chronic graft-versus-host disease (cGVHD) remains a significant complication of allogeneic hematopoietic stem cell transplantation. Central nervous system (CNS) involvement is becoming increasingly recognized, in which brain-infiltrating donor major histocompatibility complex (MHC) class II+ bone marrow-derived macrophages (BMDM) drive pathology. BMDM are also mediators of cutaneous and pulmonary cGVHD, and clinical trials assessing the efficacy of antibody blockade of colony-stimulating factor 1 receptor (CSF1R) to deplete macrophages are promising. We hypothesized that CSF1R antibody blockade may also be a useful strategy to prevent/treat CNS cGVHD. Increased blood-brain barrier permeability during acute GVHD (aGVHD) facilitated CNS antibody access and microglia depletion by anti-CSF1R treatment. However, CSF1R blockade early after transplant unexpectedly exacerbated aGVHD neuroinflammation. In established cGVHD, vascular changes and anti-CSF1R efficacy were more limited. Anti-CSF1R-treated mice retained donor BMDM, activated microglia, CD8+ and CD4+ T cells, and local cytokine expression in the brain. These findings were recapitulated in GVHD recipients, in which CSF1R was conditionally depleted in donor CX3CR1+ BMDM. Notably, inhibition of CSF1R signaling after transplant failed to reverse GVHD-induced behavioral changes. Moreover, we observed aberrant behavior in non-GVHD control recipients administered anti-CSF1R blocking antibody and naïve mice lacking CSF1R in CX3CR1+ cells, revealing a novel role for homeostatic microglia and indicating that ongoing clinical trials of CSF1R inhibition should assess neurological adverse events in patients. In contrast, transfer of Ifngr-/- grafts could reduce MHC class II+ BMDM infiltration, resulting in improved neurocognitive function. Our findings highlight unexpected neurological immune toxicity during CSF1R blockade and provide alternative targets for the treatment of cGVHD within the CNS.
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Daniel Wolff,Corey Cutler,Stephanie J. Lee,Iskra Pusic,Henrique Bittencourt,Jennifer White,Mehdi Hamadani,Sally Arai,Amandeep Salhotra,Jose A. Perez-Simon,Amin Alousi,Hannah Choe,Mi Kwon,Arancha Bermúdez,Inho Kim,Gerard Socié,Saurabh Chhabra,Vedran Radojcic,Timothy O’Toole,Chuan Tian,Peter Ordentlich,Zachariah DeFilipp,Carrie L. Kitko

DOI: https://doi.org/10.1056/nejmoa2401537

IF: 158.5

2024-09-20

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 11, Page 1002-1014, September 19, 2024.

medicine, general & internal
Selective CD28 Blockade by a Single-Chain Fv Inhibits T Cell Proliferation and Prevents Acute Rejection in a Murine Model of Cardiac Allotransplantion

T. Zhang,H. Zhou,G. Wu,R. M. O'Hara,R. N. Pierson,A. Al. Azimzadeb

DOI: https://doi.org/10.1016/j.healun.2004.11.285

2005-01-01

Abstract:A novel non-activating CD28-specific monovalent single-chain variable region antibody fragment (scFv Ab) blocks CD28 while leaving the tolerogenic CTLA4-B7 interactions unopposed. Here we explore its utility as part of a tolerance induction strategy.
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

Carrie L Kitko,Mukta Arora,Zachariah DeFilipp,Mohammad Abu Zaid,Antonio Di Stasi,Vedran Radojcic,Courtney B Betts,Lisa M Coussens,Michael L Meyers,Hope Qamoos,Peter Ordentlich,Vinit Kumar,Christine Quaranto,Aaron Schmitt,Yu Gu,Bruce R Blazar,Trent P Wang,Amandeep Salhotra,Iskra Pusic,Madan Jagasia,Stephanie J Lee

DOI: https://doi.org/10.1200/JCO.22.00958

2023-04-01

Abstract:Purpose: Chronic graft-versus-host disease (cGVHD) remains the major cause of late morbidity after allogeneic hematopoietic cell transplantation. Colony-stimulating factor 1 receptor (CSF-1R)-dependent macrophages promote cGVHD fibrosis, and their elimination in preclinical studies ameliorated cGVHD. Axatilimab is a humanized monoclonal antibody that inhibits CSF-1R signaling and restrains macrophage development. Patients and methods: This phase I (phI)/phase II (phII) open-label study (ClinicalTrials.gov identifier: NCT03604692) evaluated safety, tolerability, and efficacy of axatilimab in patients age ≥ 6 years with active cGVHD after ≥ 2 prior systemic therapy lines. Primary objectives in phI were to identify the optimal biologic and recommended phII dose and in phII to evaluate the overall (complete and partial) response rate (ORR) at the start of treatment cycle 7. Results: Forty enrolled patients (17 phI; 23 phII) received at least one axatilimab dose. In phI, a dose of 3 mg/kg given once every 4 weeks met the optimal biologic dose definition. Two dose-limiting toxicities occurred at the 3 mg/kg dose given once every 2 weeks. At least one treatment-related adverse event (TRAE) was observed in 30 patients with grade ≥ 3 TRAEs in eight patients, the majority known on-target effects of CSF-1R inhibition. No cytomegalovirus reactivations occurred. With the 50% ORR at cycle 7 day 1, the phII cohort met the primary efficacy end point. Furthermore, the ORR in the first six cycles, an end point supporting regulatory approvals, was 82%. Responses were seen in all affected organs regardless of prior therapy. Fifty-eight percent of patients reported significant improvement in cGVHD-related symptoms using the Lee Symptom Scale. On-target activity of axatilimab was suggested by the decrease in skin CSF-1R-expressing macrophages. Conclusion: Targeting profibrotic macrophages with axatilimab is a therapeutically promising novel strategy with a favorable safety profile for refractory cGVHD.
CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice

Samreen N. Shaikh,Emily F. Willis,Max Dierich,Yi Xu,Samuel J. S. Stuart,Glenda C. Gobe,Abate A. Bashaw,Oliver Rawashdeh,Seung Jae Kim,Jana Vukovic

DOI: https://doi.org/10.1186/s12974-023-02984-7

IF: 9.3

2023-12-16

Journal of Neuroinflammation

Abstract:Graft-versus-host disease (GVHD) is a serious complication of otherwise curative allogeneic haematopoietic stem cell transplants. Chronic GVHD induces pathological changes in peripheral organs as well as the brain and is a frequent cause of late morbidity and death after bone-marrow transplantation. In the periphery, bone-marrow-derived macrophages are key drivers of pathology, but recent evidence suggests that these cells also infiltrate into cGVHD-affected brains. Microglia are also persistently activated in the cGVHD-affected brain. To understand the involvement of these myeloid cell populations in the development and/or progression of cGVHD pathology, we here utilized the blood–brain-barrier permeable colony stimulating factor-1 receptor (CSF-1R) inhibitor PLX3397 (pexidartinib) at varying doses to pharmacologically deplete both cell types. We demonstrate that PLX3397 treatment during the development of cGVHD (i.e., 30 days post-transplant) improves disease symptoms, reducing both the clinical scores and histopathology of multiple cGVHD target organs, including the sequestration of T cells in cGVHD-affected skin tissue. Cognitive impairments associated with cGVHD and neuroinflammation were also attenuated by PLX3397 treatment. PLX3397 treatment prior to the onset of cGVHD (i.e., immediately post-transplant) did not change in clinical scores or histopathology. Overall, our data demonstrate significant benefits of using PLX3397 for the treatment of cGVHD and associated organ pathologies in both the periphery and brain, highlighting the therapeutic potential of pexidartinib for this condition.

immunology,neurosciences
Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease

Robert Zeiser

DOI: https://doi.org/10.1200/JCO.22.02256

2023-04-01

Abstract:The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Chronic graft-versus-host disease (cGVHD) is an immune-mediated disease that ensues after allogeneic hematopoietic cell transplantation often affecting multiple organs, decreases quality of life, and necessitates immunosuppressive therapy. The current standard first-line cGVHD therapy is glucocorticoids (GCs) which have major side effects. So far, all attempts to improve response to first-line GC therapy of cGVHD by adding other agents, such as mycophenolate mofetil, or cyclosporine A have not improved response. The data reported in the trial by Miklos et al indicate that ibrutinib should not be added to GC in first-line cGVHD therapy. The findings instruct future studies that aim at the identification of patients with cGVHD who may benefit from a GC-ibrutinib combination using biomarkers or clinical parameters. Currently, ibrutinib, ruxolitinib, and belumosudil are the only drugs that are approved by the Food and Drug Administration for steroid-refractory cGVHD. In light of the current standard management of cGVHD, the trial results indicate that ibrutinib will remain reserved for second-line therapy, which may be due to its mechanisms of action. The recommendation on the basis of this trial is that GC monotherapy remains the standard therapy for cGVHD.
Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease

Govindarajan Thangavelu,Michael C Zaiken,Fathima A Mohamed,Ryan Flynn,Jing Du,Stephanie Y Rhee,Megan J Riddle,Ethan G Aguilar,Angela Panoskaltsis-Mortari,Martin E Sanders,Bruce R Blazar

DOI: https://doi.org/10.3389/fimmu.2022.765319

2022-03-11

Abstract:Most allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients receive peripheral blood stem cell grafts resulting in a 30%-70% incidence of chronic graft-versus-host disease (cGVHD), a major cause of mortality and morbidity in long-term survivors. While systemic steroids remain the standard of care for first-line therapy, patients may require long-term administration, and those with steroid-resistant or refractory cGVHD have a worse prognosis. Although durable and deep responses with second-line therapies can be achieved in some patients, there remains an urgent need for new therapies. In this study, we evaluated the efficacy of IRX4204, a novel agonist that activates RXRs and is in clinical trials for cancer treatment to prevent and treat cGVHD in two complementary murine models. In a major histocompatibility complex mismatched, non-sclerodermatous multiorgan system model with bronchiolitis obliterans, IRX4204 prevented and reversed cGVHD including associated pulmonary dysfunction with restoration of germinal center T-follicular helper: T-follicular regulatory cell balance. In a minor histocompatibility antigen disparate sclerodermatous model, IRX4204 treatment significantly prevented and ameliorated skin cGVHD by reducing Th1 and Th17 differentiation due to anti-inflammatory properties. Together, these results indicate that IRX4204 is a promising therapeutic option to treat cGVHD with bronchiolitis obliterans or sclerodermatous manifestations.
High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Noa G. Holtzman,Lauren M Curtis,Rachel B Salit,Brian C Shaffer,Filip Pirsl,Alen Ostojic,Seth M Steinberg,Eduard Schulz,Jennifer S. Wilder,Thomas E Hughes,Jeremy Rose,Sarfraz Memon,Robert Korngold,Juan Gea-Banacloche,Daniel H Fowler,Frances T Hakim,Ronald E. Gress,Michael R. Bishop,Steven Z Pavletic

DOI: https://doi.org/10.1182/bloodadvances.2023010973

IF: 7.642

2024-04-26

Blood Advances

Abstract:Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplants (allo-HSCT). While in vivo lymphodepletion by antibodies for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced intensity conditioning (RIC) are not well described. Patients (n=83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors. Patients were randomized to two GVHD prophylaxis arms: high-dose alemtuzumab/cyclosporine (AC, n=44) and tacrolimus/methotrexate/sirolimus (TMS, n=39) with the primary endpoint of cumulative incidence of severe cGVHD. The incidence of severe cGVHD was lower with AC vs TMS prophylaxis at 1- and 5-years (0% vs 10.3% and 4.5% vs 28.5%, overall p=0.0002), as well as any grade (p=0.003) and moderate-severe (p<0.0001) cGVHD. AC was associated with higher rates of grade III-IV infections (p=0.02) and relapse (52% vs 21%, p=0.003) with a shorter 5-year PFS (18% vs 41%, p=0.01) and no difference in 5-year GRFS, OS, or NRM. AC severely depleted naïve T-cells reconstitution, resulting in reduced TCR repertoire diversity, smaller populations of CD4 Treg and CD8 Tscm, but a higher ratio of Treg to naïve T-cells at 6 months. In summary, an alemtuzumab-based regimen successfully reduced the rate and severity of cGVHD after RIC allo-HSCT and resulted in a distinct immunomodulatory profile which may have reduced cGVHD incidence and severity. However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. ClinicalTrials.gov identifier: NCT00520130

hematology
Successful management of central nervous system manifestations of chronic graft-vs-host disease: a case report

Ronak Kundalia,Anas Hanini,Syeda Saba Kareem,Rebecca Gonzalez,Tyra Gatewood,Asmita Mishra,Yolanda Pina,Sepideh Mokhtari

DOI: https://doi.org/10.1080/10428194.2023.2214828

2023-06-16

Abstract:Keywords: There are no competing interests that are directly or indirectly related to the work submitted for this publication.

oncology,hematology
Fibroblastic reticular cells orchestrate long-term graft survival following recipient treatment with CD40 ligand-targeted costimulatory blockade

Robert L Fairchild

DOI: https://doi.org/10.1172/JCI165174

2022-12-15

Abstract:Fibroblastic reticular cells (FRCs) maintain the architecture of secondary lymphoid organs, which optimize interactions between antigen-presenting dendritic cells and reactive naive T cells. In this issue of the JCI, Zhao, Jung, and colleagues investigated CD4+FoxP3+ regulatory T cell development and long-term heart allograft survival in recipients treated with peritransplant costimulatory blockade to inhibit CD40/CD40 ligand (CD40L) signaling. Treatment with an anti-CD40L monoclonal antibody (mAb) increased the lymph node (LN) population of Madcam1+ FRCs and altered their transcription profile to express immunoregulatory mediators. Administration of nanoparticles, containing the anti-CD40L mAb and a targeting antibody against high endothelial venules, delivered the treatment into LNs of allograft recipients. Direct LN delivery of the costimulatory blockade allowed decreased dosing and increased the efficacy in extending graft survival. The results provide insights into mechanisms by which FRCs can promote donor-reactive tolerance, and establish a strategy for administering costimulation-blocking reagents that circumvent systemic effects and improve allograft outcomes.
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment

Maria Del Mar Maldonado,Jeffrey Schlom,Duane H Hamilton

DOI: https://doi.org/10.1007/s00262-023-03496-2

Abstract:The macrophage colony-stimulating factor 1 (CSF1) is a chemokine essential for the survival, proliferation, and differentiation of mononuclear phagocytes from hemopoietic stem cells. In addition to its essential physiological role in normal tissues, the CSF1/CSF1 receptor axis is known to be overexpressed in many tumor types and associated with poor prognosis. High levels of CSF1 within the tumor microenvironment have been shown to recruit and reeducate macrophages to produce factors that promote tumor invasiveness and accelerate metastasis. In this study, we demonstrate, for the first time, that treating established syngeneic murine colon and breast carcinoma tumors with a CSF1R-blocking antibody also promotes the expansion of neoepitope-specific T cells. To assess the role of tumor-derived CSF1 in these model systems, we generated and characterized CSF1 CRISPR-Cas9 knockouts. Eliminating tumor-derived CSF1 results in decreased tumor growth and enhanced immunity against tumor-associated neoepitopes, potentially promoting an immune permissive tumor microenvironment in tumor-bearing mice. The combination of neoepitope vaccine with anti-PDL1 in the MC38 CSF1-/- tumor model significantly decreased tumor growth in vivo. Moreover, anti-CSF1R therapy combined with the adeno-TWIST1 vaccine resulted in tumor control, decreased metastasis, and a synergistic increase in CD8 T cell infiltration in 4T1 mammary tumors. Analysis of the tumor microenvironment demonstrated greater CD8 T cell infiltration and a reduction in tumor-associated macrophages following CSF1R inhibition in both tumor models. Our findings thus add to the therapeutic potential of CSF1 targeting agents by employing combinations with vaccines to modulate anti-neoepitope responses in the tumor microenvironment.
The brain may devise laws for the blood

David S Ritchie,David S. Ritchie

DOI: https://doi.org/10.1182/blood.2023023291

IF: 20.3

2024-03-08

Blood

Abstract:In this issue of Blood , Adams and colleagues have explored the impact of monoclonal antibody blockade of colony-stimulating factor 1 receptor (CSF1R) in models of central nervous system (CNS) chronic graft-versus-host disease (cGVHD). 1 Chronic GVHD is a pervasive syndrome of destructive donor-derived immune activation, uncontrolled acute and chronic inflammation, and progressive organ dysfunction following allogeneic stem cell transplantation. Overall, cGVHD is a major cause of mortality and morbidity following allogeneic stem cell transplantation and the major cause of impairment of activities of daily living and reduced quality-of-life measures. 2 , 3 Prior modeling from the same laboratory as the current article has determined that CNS cGVHD is driven by a unique population of CSF1-dependent, brain-infiltrating, bone marrow-derived major histocompatibility complex (MHC) class II-positive macrophages (BMDM), which promote a late CD4 + T-cell CNS infiltration and interferon gamma (IFN-γ)-dependent chronic neuroinflammation, impaired neurological synapse function, and impaired behavior. 4

hematology
Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model

Jing Yuan,Han-yun Ren,Yong-jin Shi,Wei Liu

DOI: https://doi.org/10.1007/s00011-014-0793-6

2015-01-01

Abstract:Objective One characteristic feature of graft-versus-host disease (GVHD) is lymphocytes’ trafficking and recruitment to target tissues, and CCR5 plays a key role in the process. Thus, blockade of lymphocytes’ chemotaxis may attenuate GVHD. Methods We tested the effects of CCR5 blockade using an established murine model. The mean survival time, body weight change, and clinical GVHD scores were assessed. Concentrations of cytokines and chemokines, the CCR5, CXCR3, and CCR7 expressions on T lymphocytes, and histological changes of visceral organs were also evaluated. Additionally, we assessed the immunophenotype of infiltration cells in liver and intestine. Results Mice undergoing total body irradiation and allogenic hematopoietic stem cell transplantation (allo-HSCT) developed typical GVHD. MVC increased CCR5 expression whereas CCR7 and CXCR3 expression were unaffected. MVC also increased plasma levels of the ligands of CCR5. A combination of MVC with CsA significantly alleviated the degree of visceral injuries and prolonged survival time. Conclusion MVC has a synergistic effect with CsA. It can attenuate the severity of GVHD and increase survival rate of mice in our murine model. This may offer a novel therapeutic perspective for clinical GVHD after allo-HSCT.
CXCR3 Blockade Combined with Cyclosporine A Alleviates Acute Graft-Versus-host Disease by Inhibiting Alloreactive Donor T Cell Responses in a Murine Model

Shengchao Miao,Bo Tang,Huihui Liu,Zhenhua Wang,Yongjin Shi,Yujun Dong,Wei Liu,Chenchen Qin,Hanyun Ren

DOI: https://doi.org/10.1016/j.molimm.2017.12.010

IF: 4.174

2018-01-01

Molecular Immunology

Abstract:Chemotaxis of T cells to acute graft-versus-host disease (aGvHD) target tissues directed by chemokines and their receptors plays a key role in the pathogenesis of aGvHD. Blockade of lymphocyte migration by targeting chemokine receptors may be a viable strategy for the prevention and treatment of aGvHD, which is quite distinguishable from typical efforts to use immunosuppressive medications that have been associated with some side effects. CXCR3 and its ligands have been reported to be correlated with aGvHD pathogenesis. Using the small-molecule CXCR3 antagonist AMG487, we demonstrated that AMG487 combined with cyclosporine A (CsA) effectively alleviated aGvHD with a prolonged mean survival time and significantly inhibited the infiltration of inflammatory cells in aGvHD target tissues in a murine aGvHD model. In addition, AMG487 combined with CsA inhibited the activation, proliferation and differentiation of donor-derived T cells in the spleens. Further results showed that the concentrations of Th1 cells associated with pro-inflammatory cytokines such as IFN-γ and TNFα in serum were decreased. In addition, AMG487 treatment did not alter CXCR3 and CCR5 expression in donor-derived T cells but elevated the serum CXCL9 and CXCL10 levels. This novel and effective approach has the potential to develop a new clinical method to prevent and treat aGvHD.
Dual‐Targeting Nanovesicles Carrying CSF1/CD47 Identified from Single‐Cell Transcriptomics of Innate Immune Cells in Heart Transplant for Alleviating Acute Rejection

Zhanxue Xu,Xiaofan Mao,Xingyu Lu,Peilin Shi,Jingping Ye,Xinrui Yang,Qingling Fu,Chao He,Dandan Su,Yichu Nie,Longshan Liu,Changxi Wang,Benjie Zhou,Wei Luo,Fang Cheng,Hongbo Chen

DOI: https://doi.org/10.1002/adhm.202302443

IF: 10

2023-11-14

Advanced Healthcare Materials

Abstract:Abstract Although immunosuppressive drugs for targeting T cells are the standard of care in acute transplantation rejection, the role of innate immune cells should not be ignored. Here, we performed single‐cell RNA sequencing (scRNA‐seq) and flow cytometry to reveal the dynamic changes of innate immune cells within the acute rejection time and found a significantly‐increased presence of Ly6G − Ly6C + inflammatory macrophages and decreased presence of neutrophils among all types of immune cells. Next, to further explore potential targets regulating Ly6G − Ly6C + inflammatory macrophages, scRNA‐seq was used to analyze the reciprocal signaling of both neutrophils and macrophages, along with the surface genes of macrophages. We found that activating CSF1/CSF1R and CD47/SIRPα signaling may serve as a strategy to relieve Ly6G − Ly6C + inflammatory macrophage‐mediated early graft rejection. To investigate this hypothesis, CSF1/CD47 dual‐targeting nanovesicles (NVs) derived from IFN‐γ‐stimulated iPSC‐MSCs were designed and constructed. We confirmed that CSF1/CD47 NVs synergistically induced the differentiation of Ly6G − Ly6C − M2 inhibitory macrophages by the CSF1/CSF1R pathway, and inhibited the phagocytosis of inflammatory macrophages and inflammatory response by the CD47/SIRPα pathway, ultimately relieving immune rejection. Our study highlights the power of dual‐targeting CSF1/CD47 NVs as an immunosuppressant against early innate immune responses with the potential for broad clinical applications. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Ex Vivo Inhibition of NF-κB Signaling in Alloreactive T-cells Prevents Graft-Versus-Host Disease

M. J. O'Shaughnessy,C. Vogtenhuber,K. Sun,R. Sitcheran,A. S. Baldwin,W. J. Murphy,L. Dang,B. Jaffee,E. Palmer,J. S. Serody,B. R. Blazar

DOI: https://doi.org/10.1111/j.1600-6143.2008.02533.x

2009-01-01

Abstract:The ex vivo induction of alloantigen-specific hyporesponsiveness by costimulatory pathway blockade or exposure to immunoregulatory cytokines has been shown to inhibit proliferation, IL-2 production, and the graft-versus-host disease (GVHD) capacity of adoptively transferred T-cells. We hypothesized that inhibition of the intracellular NF-kappaB pathway in alloreactive T-cells, which is critical for T-cell activation events including IL-2 transcription, could lead to alloantigen hyporesponsiveness and loss of GVHD capacity. We demonstrate that treatment of mixed lymphocyte reaction (MLR) cultures with PS1145, a potent inhibitor of NF-kappaB activation, can induce T-cell hyporesponsiveness to alloantigen in primary and secondary responses while preserving in vitro responses to potent mitogenic stimulation. GVHD lethality in recipients of ex vivo PS1145-treated cells was profoundly inhibited. Parking of control or PS1145-treated MLR cells in syngeneic Rag(-/-) recipients resulted in intact contact hypersensitivity (CHS) responses. However, GVHD lethality capacity also was restored, suggesting that lymphopenic expansion uncoupled alloantigen hyporesponsiveness. These results indicate that the NF-kappaB pathway is a critical regulator of alloresponses and provide a novel small molecule inhibitor based approach that is effective in preventing early posttransplant GVHD lethality but that also permits donor T-cell responses to recover after a period of lymphopenic expansion.
Case report: Use of granulocyte-colony stimulating factor as an immunomodulatory therapy in a patient with neuromyelitis optica spectrum disorder and comorbid immunodeficiency

Gina S. Perez Giraldo,Edith L. Graham,Stephen VanHaerents,Roumen Balabanov

DOI: https://doi.org/10.3389/fneur.2023.1240356

IF: 3.4

2023-09-21

Frontiers in Neurology

Abstract:Background: Autoimmune diseases can coexist with immunodeficiency. We describe a treatment approach in which granulocyte-colony stimulating factor (G-CSF) is used to restore immune competence without worsening autoimmunity. G-CSF is a polyfunctional cytokine that influences survival, proliferation, and differentiation of hematopoietic stem cells, and has immunomodulatory effects on the innate and adaptive immune systems. Objective: To report a case of neuromyelitis optica spectrum disorder (NMOSD) with comorbid immunodeficiency and frequent infections. Methods: Case report and review of literature. Results: A 23 years-old man presented with a focal onset seizure with impaired awareness at age 12. At age 18, he developed headaches, recurrent multifocal seizures, and non-convulsive status epilepticus. Brain magnetic resonance imaging (MRI) showed extensive T2 hyperintense and gadolinium-enhancing periventricular and corpus callosum lesions. Serum aquaporin 4 antibody was positive 1:10,000 (normal value <1.5 titer), hence he was diagnosed with NMOSD. As a complication, patient developed mucormycotic pneumonia with cavitation, requiring thoracotomy precluding use of immunosuppressants. Gene testing demonstrated a mutation in MT-ND4 gene encoding for NADH dehydrogenase 4 in mitochondrial complex 1. Eventually, he began a treatment with filgrastim, a G-CSF analog, in addition to intravenous immunoglobulins and prednisone. Patient's NMOSD has been in remission without relapses, or coexistent infections ever since. Conclusion: G-CSF is a polyfunctional cytokine with important immunomodulatory effects, which makes it an interesting therapeutic option when autoimmunity coexists with immunodeficiency and was used successfully in this case.

neurosciences,clinical neurology

CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Targeting CSF1R in Chronic GVHD — Lessons in Translation

CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Selective CD28 Blockade by a Single-Chain Fv Inhibits T Cell Proliferation and Prevents Acute Rejection in a Murine Model of Cardiac Allotransplantion

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice

Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease

Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease

High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Successful management of central nervous system manifestations of chronic graft-vs-host disease: a case report

Fibroblastic reticular cells orchestrate long-term graft survival following recipient treatment with CD40 ligand-targeted costimulatory blockade

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment

The brain may devise laws for the blood

Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model

CXCR3 Blockade Combined with Cyclosporine A Alleviates Acute Graft-Versus-host Disease by Inhibiting Alloreactive Donor T Cell Responses in a Murine Model

Dual‐Targeting Nanovesicles Carrying CSF1/CD47 Identified from Single‐Cell Transcriptomics of Innate Immune Cells in Heart Transplant for Alleviating Acute Rejection

Ex Vivo Inhibition of NF-κB Signaling in Alloreactive T-cells Prevents Graft-Versus-Host Disease

Case report: Use of granulocyte-colony stimulating factor as an immunomodulatory therapy in a patient with neuromyelitis optica spectrum disorder and comorbid immunodeficiency